Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site within 30 days of treatment that demonstrates positive STAT5 activation status
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotwór gruczołu krokowego (rak prostaty)
- •Przerzuty raka widoczne w badaniach obrazowych (USG, CT, MRI lub PET)
- •Rak rozwijał się mimo leczenia hormonalnego i przynajmniej jednego leku z grupy inhibitorów receptora androgenowego
- •Niski poziom testosteronu we krwi (poniżej 50 ng/dL)
- •Dobry ogólny stan zdrowia (stopień wydolności 0-1 wg skali ECOG)
- •Nigdy wcześniej nie leczony lekami inhibującymi kinazę JAK2
- •Prawidłowa funkcja serca, wątroby i nerek w badaniach laboratoryjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Froedtert & the Medical College of Wisconsin
Milwaukee, United States
Trial contact
Medical College of Wisconsin Cancer Center Clinical Trials Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.